ATYR

Dopo l'orario di chiusura: 1.75 -0.01 -0.57%

Atyr Pharma Inc (ATYR)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Atyr Pharma Inc Stock (ATYR) Company Profile

Atyr Pharma Inc

(858) 731-8389

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Prossima data di guadagno

Ultimi documenti SEC

ATYR's Discussions on Twitter

Atyr Pharma Inc Borsa (ATYR) Ultime notizie

Atyr Pharma Inc Azioni (ATYR) Dati Finanziari

Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.

Atyr Pharma Inc (ATYR)

Atyr Pharma Inc Stock (ATYR) Company Profile

Atyr Pharma Inc Borsa (ATYR) Ultime notizie

Wall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risks - Investing.com

Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5% - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat

Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Aarti Drugs gets 7 observation from USFDA for Tarapur plant - NewsDrum

Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World

A look into Atricure Inc (ATRC)’s deeper side - SETE News

First Light Asset Management LLC Grows Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Aarti Drugs shares trade lower after 7 observations from USFDA - Moneycontrol

Buying Buzz: Atyr Pharma Inc [ATYR] Director SCHIMMEL PAUL purchases 52,300 shares of the company - Knox Daily

Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Atyr PHARMA (ATYR) versus Its Competitors Critical Survey - Defense World

Aster DM Health, Quality CARE inching closer to a merger deal - The Economic Times

Atyr PHARMA (ATYR) and Its Rivals Head to Head Analysis - Defense World

Atyr PHARMA (NASDAQ:ATYR) versus Exscientia (NASDAQ:EXAI) Critical Survey - Defense World

Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat

Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily

ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha

Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily

Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News

Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex

Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World

Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada

Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat

Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN

Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World

Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News

Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World

Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World

Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK

aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire

aTyr Pharma to Participate in September Investor Conferences - StockTitan

ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com

Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com

Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex

aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com

ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com

Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World

Atyr Pharma Inc Azioni (ATYR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ATYR